TITLE

The P450 system and CV outcomes with clopidogrel

PUB. DATE
January 2011
SOURCE
Primary Care Reports;Jan2011 Clinical Briefs in Primary, Vol. 16 Issue 1, p1
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article discusses a research study conducted on subjects with atrial fibrillation or post-acute coronary syndrome (ACS) who were exposed to clopidogrel and received CYP2C19, concluding that the P450 system and clopidogrel do not ensure positive effects on cardiovascular outcomes or bleeding risk.
ACCESSION #
58593207

 

Related Articles

  • Health economic analysis of ticagrelor in patients with acute coronary syndromes intended for non-invasive therapy. Janzon, M.; James, S.; Cannon, C. P.; Storey, R. F.; Mellström, C.; Nicolau, J. C.; Wallentin, L.; Henriksson, M. // Heart;1/15/2015, Vol. 101 Issue 2, p119 

    Objective To investigate the cost effectiveness of ticagrelor versus clopidogrel in patients with acute coronary syndromes (ACS) in the Platelet Inhibition and Patient Outcomes (PLATO) study who were scheduled for non-invasive management. Methods A previously developed cost effectiveness model...

  • Diagnostic accuracy of mean platelet volume in prediction of clopidogrel resistance in patients with acute coronary syndrome. Uzel, Hazel; Özpelit, Ebru; Badak, Özer; Akdeniz, Bahri; Barış, Nezihi; Aytemiz, Fatih; Göldeli, Özhan // Anatolian Journal of Cardiology / Anadolu Kardiyoloji Dergisi;Mar2014, Vol. 14 Issue 2, p134 

    Objective: Clopidogrel therapy is the standard of care in patients with acute coronary syndrome (ACS) and stent implantation. However, concern arises because 25% of subjects are nonresponders to clopidogrel. As this nonresponsiveness is associated with increased adverse outcome, detection of...

  • Cardiorenal syndrome: a silent but deadly complication in acute coronary syndrome patients. Lourenco, C.N.; Teixeira, R.; Antonio, N.; Monteiro, S.; Batista, R.; Jorge, E.; Monteiro, P.; Goncalves, L.; Freitas, M.; Providencia, L.A. // European Journal of Heart Failure. Supplements;Jun2008, Vol. 7 Issue 1, p95 

    An abstract of the article "Cardiorenal syndrome: a silent but deadly complication in acute coronary syndrome patients," by C. N. Laurenco and colleagues is presented.

  • Q/When you suspect ACS, which serologic marker is best? Mitchell, Jonathan; Mounsey, Anne; Mackler, Leslie // Journal of Family Practice;Feb2014, Vol. 63 Issue 2, p106 

    The article provides an answer to a question about the most accurate serologic marker that can be used in examining patient with acute coronary syndrome (ACS).

  • Factors influencing the use of ambulance among patients with acute coronary syndrome: results of two centers in Turkey. Ünlüoğlu, İlhami; Kaba, Hamdi // Anatolian Journal of Cardiology / Anadolu Kardiyoloji Dergisi;May2014, Vol. 14 Issue 3, p309 

    A letter to the editor is presented in response to the article related to the factors influencing the use of ambulance among patients with acute coronary syndrome by B. Demirkan and others that was published in a 2013 issue of the periodical along with the author's reply.

  • Fatigue in a Patient with Atrial Fibrillation. Germano, Joseph J.; Steingart, Richard M. // Cortlandt Forum;8/25/2002, Vol. 15 Issue 8, p68 

    Describes a case of fatigue in a patient with atrial fibrillation. Reason for administration of amiodarone; Multiorgan side effects of amiodarone; Characteristics and physiologic effects of amiodarone.

  • The P450 system and CV outcomes with clopidogrel. Kuritzky, Louis // Internal Medicine Alert;12/15/2010 Supplement, p183 

    The article offers information on the impact of the P450 system and clopidogrel on the reduction of cardio-vascular events (CV) among people with atrial fibrillation.

  • Risk assessment for bleeding during warfarin therapy. Kuritzky, Louis // Internal Medicine Alert;12/15/2010 Supplement, p183 

    The article offers information on the role of the HAS-BLED stratification tool in evaluating one-year risk of bleeding in patients with atrial fibrillation (AF) who were undergoing warfarin therapy.

  • Rivaroxaban Tablets (Xarelto®). Elliott, William T.; Chan, James // Internal Medicine Alert;12/15/2011, Vol. 33 Issue 23, p181 

    The article reports that an oral factor xa inhibitor named Rivaroxaban has been approved for minimizing the risk of stroke and systemic embolism in patients suffering from atrial fibrillation (AF).

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics